

Rec'd PCT PTO 29 DEC 2004

518.386

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002475 A1

(51) International Patent Classification⁷: A61K 31/404, 9/20

(74) Agent: DOSKOCZYNsKA-GROYECKA, Anna; ul. Zaleskiego 9/3, PL-31-525 Kraków (PL).

(21) International Application Number:
PCT/PL2002/000056

(81) Designated States (national): BA, EE, HR, HU, LT, LV, MK, RU, SI, UA, US.

(22) International Filing Date: 24 July 2002 (24.07.2002)

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(25) Filing Language: English

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i)) for the following designations BA, EE, HR, HU, LT, LV, MK, RU, SI, UA, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): PLIVA KRAKÓW, ZAKLADY FARMACEUTYCZNE S.A. [PL/PL]; ul. Mogilska 80, PL-31-456 Kraków (PL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): JURECZEK, Katarzyna [PL/PL]; ul. Lasówka 44/13, PL-30-718 Kraków (PL).

WO 2004/002475 A1

(54) Title: SUSTAINED RELEASE TABLET CONTAINING INDAPAMIDE

(57) **Abstract:** The present invention relates to a sustained release tablet containing indapamide and the process of manufacturing sustained release tablet containing indapamide. The tablet contains indapamide in the amount of 1.5 to 2.5% of the total mass of the tablet, lactose monohydrate in the amount of 30 to 80% of the total mass of the tablet, copovidone in the amount of 2 to 10% of the total mass of the tablet, hypromellose in the amount of 20 to 65% of the total mass of the tablet and lubricants in the amount of 0.1 to 5% of the total mass of the tablet. The process of manufacturing the sustained release tablet consists in mixing of indapamide with lactose monohydrate and copovidone and then, the mixture is moistened by purified water and the granulation process of it is performed. Next the granulate is dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine. (4 claims)